Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06687980 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
A Phase 3 study of Lichen Simplex Chronicus, sponsored by Sanofi.
- Active
- Registry status
- Phase 3
- Development phase
- 138
- Enrollment target
- 20
- Study locations
NCT06687980 is a Phase 3 study of Lichen Simplex Chronicus that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 138 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT06687980, a Phase 3 study of Lichen Simplex Chronicus, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 138 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged at least 18 years with LSC. Study details include: The study duration will be up to 40 weeks. The treatment duration will be up to 24 weeks. The follow-up duration after treatment will be 12 weeks. The number of visits will be 6.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dupilumab
Study Locations (20)
Other
- Investigational Site Number : 0320201 - Buenos Aires
- Investigational Site Number : 0320203 - Córdoba
- Investigational Site Number : 0560202 - Alken
- Investigational Site Number : 0560203 - Maldegem
Texas
- Bellaire Dermatology Associates,- Site Number : 8400202 - Bellaire
- Austin Institute for Clinical Research - Pflugerville- Site Number : 8400203 - Pflugerville
- Progressive Clinical Research - San Antonio- Site Number : 8400206 - San Antonio
California
- Cosmetic Dermatology of Orange County- Site Number : 8400232 - Anaheim
- Center for Dermatology Clinical Research- Site Number : 8400226 - Fremont
Florida
- University of Miami Miller School of Medicine- Site Number : 8400218 - Miami
- TrueBlue Clinical Research- Site Number : 8400208 - Tampa
Alberta
- Investigational Site Number : 1240210 - Calgary
- Investigational Site Number : 1240207 - Edmonton
Georgia
- Skin Care Physicians of Georgia - Macon- Site Number : 8400236 - Macon
Indiana
- Southern Indiana Clinical Research Center- Site Number : 8400230 - Columbus
Kentucky
- Equity Medical - Bowling Green- Site Number : 8400240 - Bowling Green
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2024-11-25 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06687980
The ClinicalTrials.gov registry entry for NCT06687980 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lichen Simplex Chronicus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06687980 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06687980 about?
NCT06687980 is a clinical study titled "A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)". This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged at least 18 years with LSC. Study details include: The study duration...
What is the current status of trial NCT06687980?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 138 participants. The study started on 2024-11-25. Estimated completion is 2026-08-31.
What conditions does trial NCT06687980 study?
This clinical trial studies the following conditions: Lichen Simplex Chronicus.
What interventions are being tested in trial NCT06687980?
The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG).
Who is sponsoring clinical trial NCT06687980?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06687980 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lichen Simplex Chronicus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.